TIGI 50 mg INJECTION 

Tigi is an antibiotic that fights bacteria in the body. It works by killing sensitive bacteria.

MEDICINE USES :

Tigecycline is used to treat many different bacterial infections of the skin or the digestive system, as well as pneumonia.

NATCO TIGECYCLINE 50 mg SIDE EFFECTS :

    nausea, vomiting, stomach pain;
    diarrhea;
    headache; or
    abnormal liver function tests
    severe stomach pain, diarrhea that is watery or bloody;
    increased pressure inside the brain – severe headache, ringing in your ears, dizziness, nausea, vision problems, pain behind your eyes;
    pancreas problems – severe pain in your upper stomach spreading to your back, nausea and vomiting, fast heart rate; or
    liver problems – nausea, upper stomach pain, itching, tired feeling, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.

SAFETY INFORMATION (Precautions) for TIGI TIGECYCLINE INJECTION :

    Before using Tigecycline, tell your doctor or pharmacist if you are allergic to it; or to tetracyclines (such as doxycycline, minocycline, tetracycline); or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.
    Before using this medication, tell your doctor or pharmacist your medical history, especially of: severe liver disease.
    This drug may make you dizzy. Do not drive, use machinery, or do any activity that requires alertness until you are sure you can perform such activities safely. Limit alcoholic beverages.
    This medication may make you more sensitive to the sun. Avoid prolonged sun exposure, tanning booths or sunlamps. Use a sunscreen and wear protective clothing when outdoors.
    Before having surgery, tell your doctor or dentist that you are using this medication.
    This medication should not be used in children younger than 8 years of age because it may cause permanent tooth discoloration and other problems. Tooth discoloration may also occur in older children and young adults. Consult your doctor for more information.
    This medication is not recommended for use during pregnancy because of possible harm to an unborn baby. Consult your doctor for more details.
    It is not known whether this drug passes into breast milk. Because of possible harm to a nursing infant, consult your doctor before breast-feeding.

This is not a complete list. Ask your health care provider for more information.

STORAGE REQUIREMENTS :

Tigecycline should be stored at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F).

DRUG INTERACTIONS :

Some products that may interact with this drug include: “blood thinners” (e.g., warfarin), live bacterial vaccines, retinoid medications taken by mouth (such as acitretin, isotretinoin).

This document does not contain all possible interactions. Keep a list of all your medications with you, and share the list with your doctor and pharmacist.

Tivozanib, sold under the brand name Fotivda, is a medication used for the treatment of relapsed or refractory advanced renal cell carcinoma (RCC). It is an oral VEGF receptor tyrosine kinase inhibitor

What are Tivozanib Capsules used for?

Tivozanib Capsules are used to treat advanced renal cell carcinoma (RCC; cancer that begins in the kidneys) that has returned or did not respond to at least two other medications. Tivozanib is in a class of medications called kinase inhibitors.

When was Tivozanib approved?

On March 10, 2021, the FDA granted regular approval to tivozanib for the treatment of patients with relapsed or refractory (R/R) advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.

Can renal cell carcinoma go into remission?

Abstract. Complete remission (CR) is uncommon during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs), but it may occur in some patients. It remains a matter of debate whether therapy should be continued after CR.

Who manufactures Tivozanib?

Tivozanib in RCC

AVEO received U.S. Food and Drug Administration approval for FOTIVDA in March 2021 for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.

The most common side effects include fatigue, hypertension, diarrhea, decreased appetite, nausea, dysphonia, hypothyroidism, cough, and stomatitis.

ONLY FOR INFORMATION PURPOSES